SINPHAR (1734) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 杏輝

SINPHAR (1734) reported revenue of NT$295.9 million for Oct 2026, +8.2% year on year and +16.3% from the previous month. Revenue for Jan–Oct 2026 was NT$2.84 billion (+2.7% year on year).

In Oct 2026, it ranked No. 33 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$289.3 million24/10Nov 2024 NT$272.6 millionDec 2024 NT$291.3 millionJan 2025 NT$266.3 millionFeb 2025 NT$237.5 million25/02Mar 2025 NT$301.8 millionApr 2025 NT$271 millionMay 2025 NT$272.6 millionJun 2025 NT$268.5 million25/06Jul 2025 NT$291.7 millionAug 2025 NT$255.8 millionSep 2025 NT$328.5 millionOct 2025 NT$273.5 million25/10Nov 2025 NT$281.3 millionDec 2025 NT$322.5 millionJan 2026 NT$312.8 millionFeb 2026 NT$196.3 million26/02Mar 2026 NT$317.2 millionApr 2026 NT$291.5 millionMay 2026 NT$300.8 millionJun 2026 NT$278.6 million26/06Jul 2026 NT$283.4 millionAug 2026 NT$311 millionSep 2026 NT$254.4 millionOct 2026 NT$295.9 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$295.9 million+8.2%+16.3%
Sep 2026NT$254.4 million-22.5%-18.2%
Aug 2026NT$311 million+21.6%+9.8%
Jul 2026NT$283.4 million-2.9%+1.7%
Jun 2026NT$278.6 million+3.8%-7.4%
May 2026NT$300.8 million+10.3%+3.2%
Apr 2026NT$291.5 million+7.6%-8.1%
Mar 2026NT$317.2 million+5.1%+61.6%
Feb 2026NT$196.3 million-17.4%-37.2%
Jan 2026NT$312.8 million+17.4%-3.0%
Dec 2025NT$322.5 million+10.7%+14.6%
Nov 2025NT$281.3 million+3.2%+2.9%
Oct 2025NT$273.5 million-5.5%-16.7%
Sep 2025NT$328.5 million+56.7%+28.4%
Aug 2025NT$255.8 million-8.8%-12.3%
Jul 2025NT$291.7 million+11.7%+8.6%
Jun 2025NT$268.5 million-0.3%-1.5%
May 2025NT$272.6 million+6.1%+0.6%
Apr 2025NT$271 million+12.3%-10.2%
Mar 2025NT$301.8 million+13.0%+27.1%
Feb 2025NT$237.5 million+14.7%-10.8%
Jan 2025NT$266.3 million-12.3%-8.6%
Dec 2024NT$291.3 million+18.0%+6.9%
Nov 2024NT$272.6 million+3.7%-5.8%
Oct 2024NT$289.3 million+21.4%+38.0%

Jan–Oct 2026 cumulative: NT$2.84 billion (+2.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: SINPHAR vs PEC / SINPHAR vs Lotus Pharm / SINPHAR vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16